Cargando…

Effect of dextran-70 on outcome in severe sepsis; a propensity-score matching study

BACKGROUND: Albumin may be beneficial in patients with septic shock but availability is limited and cost is high. The objective of the present study was to investigate if the use of dextran-70 in addition to albumin and crystalloids influences organ failure or mortality in patients with severe sepsi...

Descripción completa

Detalles Bibliográficos
Autores principales: Bentzer, Peter, Broman, Marcus, Kander, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501466/
https://www.ncbi.nlm.nih.gov/pubmed/28683810
http://dx.doi.org/10.1186/s13049-017-0413-x
_version_ 1783248788409810944
author Bentzer, Peter
Broman, Marcus
Kander, Thomas
author_facet Bentzer, Peter
Broman, Marcus
Kander, Thomas
author_sort Bentzer, Peter
collection PubMed
description BACKGROUND: Albumin may be beneficial in patients with septic shock but availability is limited and cost is high. The objective of the present study was to investigate if the use of dextran-70 in addition to albumin and crystalloids influences organ failure or mortality in patients with severe sepsis or septic shock. METHODS: Patients with severe sepsis or septic shock (n = 778) admitted to a university hospital intensive care unit (ICU) between 2007 and 2015 that received dextran-70 during resuscitation were propensity score matched to controls at a 1 to 1 ratio. Outcomes were highest acute kidney injury network (AKIN) score the first 10 days in the ICU, use of renal replacement therapy, days alive and free of organ support the first 28 days after admission to ICU, mortality and events of severe bleeding. Outcomes were assessed using paired hypothesis testing. RESULTS: Propensity score matching resulted in two groups of patients with 245 patients in each group. The dextran group received a median volume of 1483 ml (interquartile range, 1000–2000 ml) of dextran-70 during the ICU stay. Highest AKIN score did not differ between the control- and dextran groups (1 (0–3) versus 2 (0–3), p = 0.06). Incidence of renal replacement therapy in the control- and dextran groups was similar (19% versus 22%, p = 0.42, absolute risk reduction −2.9% [95% CI: −9.9 to 4.2]). Days alive and free of renal replacement, vasopressors and mechanical ventilation did not differ between the control- and dextran groups. The 180-day mortality was 50.2% in the control group and 41.6% in the dextran group (p = 0.046, absolute risk reduction 8.6% [−0.2 to 17.4]). Fraction of patients experiencing a severe bleeding in the first 10 days in the ICU did not differ between the control and dextran groups (14% versus 18%, p = 0.21). DISCUSSION: There is a paucity of high quality data regarding effects of dextran solutions on outcome in sepsis. In the present study, propensity score matching was used in attempt to reduce bias. CONCLUSION: No evidence to support a detrimental effect of dextran-70 on mortality or on organ failures in patients with severe sepsis or septic shock could be detected. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13049-017-0413-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5501466
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55014662017-07-10 Effect of dextran-70 on outcome in severe sepsis; a propensity-score matching study Bentzer, Peter Broman, Marcus Kander, Thomas Scand J Trauma Resusc Emerg Med Original Research BACKGROUND: Albumin may be beneficial in patients with septic shock but availability is limited and cost is high. The objective of the present study was to investigate if the use of dextran-70 in addition to albumin and crystalloids influences organ failure or mortality in patients with severe sepsis or septic shock. METHODS: Patients with severe sepsis or septic shock (n = 778) admitted to a university hospital intensive care unit (ICU) between 2007 and 2015 that received dextran-70 during resuscitation were propensity score matched to controls at a 1 to 1 ratio. Outcomes were highest acute kidney injury network (AKIN) score the first 10 days in the ICU, use of renal replacement therapy, days alive and free of organ support the first 28 days after admission to ICU, mortality and events of severe bleeding. Outcomes were assessed using paired hypothesis testing. RESULTS: Propensity score matching resulted in two groups of patients with 245 patients in each group. The dextran group received a median volume of 1483 ml (interquartile range, 1000–2000 ml) of dextran-70 during the ICU stay. Highest AKIN score did not differ between the control- and dextran groups (1 (0–3) versus 2 (0–3), p = 0.06). Incidence of renal replacement therapy in the control- and dextran groups was similar (19% versus 22%, p = 0.42, absolute risk reduction −2.9% [95% CI: −9.9 to 4.2]). Days alive and free of renal replacement, vasopressors and mechanical ventilation did not differ between the control- and dextran groups. The 180-day mortality was 50.2% in the control group and 41.6% in the dextran group (p = 0.046, absolute risk reduction 8.6% [−0.2 to 17.4]). Fraction of patients experiencing a severe bleeding in the first 10 days in the ICU did not differ between the control and dextran groups (14% versus 18%, p = 0.21). DISCUSSION: There is a paucity of high quality data regarding effects of dextran solutions on outcome in sepsis. In the present study, propensity score matching was used in attempt to reduce bias. CONCLUSION: No evidence to support a detrimental effect of dextran-70 on mortality or on organ failures in patients with severe sepsis or septic shock could be detected. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13049-017-0413-x) contains supplementary material, which is available to authorized users. BioMed Central 2017-07-06 /pmc/articles/PMC5501466/ /pubmed/28683810 http://dx.doi.org/10.1186/s13049-017-0413-x Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Research
Bentzer, Peter
Broman, Marcus
Kander, Thomas
Effect of dextran-70 on outcome in severe sepsis; a propensity-score matching study
title Effect of dextran-70 on outcome in severe sepsis; a propensity-score matching study
title_full Effect of dextran-70 on outcome in severe sepsis; a propensity-score matching study
title_fullStr Effect of dextran-70 on outcome in severe sepsis; a propensity-score matching study
title_full_unstemmed Effect of dextran-70 on outcome in severe sepsis; a propensity-score matching study
title_short Effect of dextran-70 on outcome in severe sepsis; a propensity-score matching study
title_sort effect of dextran-70 on outcome in severe sepsis; a propensity-score matching study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501466/
https://www.ncbi.nlm.nih.gov/pubmed/28683810
http://dx.doi.org/10.1186/s13049-017-0413-x
work_keys_str_mv AT bentzerpeter effectofdextran70onoutcomeinseveresepsisapropensityscorematchingstudy
AT bromanmarcus effectofdextran70onoutcomeinseveresepsisapropensityscorematchingstudy
AT kanderthomas effectofdextran70onoutcomeinseveresepsisapropensityscorematchingstudy